Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Infectious Diseases Spain Clinical Trials

Gilead's quad pill for HIV non-inferior to Atripla in Phase II

This article was originally published in Scrip

Executive Summary

Gilead Sciences' new "quad" pill combination drug for HIV – which combines its investigational integrase inhibitor elvitegravir, emtricitabine, tenofovir disoproxil fumarate and its new experimental boosting agent GS-9350 – is non-inferior to its three drug standard combination Atripla (efavirenz plus emtricitabine plus tenofovir), show top-line results. The company notes that result for a separate phase II trial of the GS-9350 booster were also positive.

Table

View full table

Topics

Related Companies

Tags:
Infectious Diseases Spain Clinical Trials
Latest Headlines

Amgen Planning Pivotal Obesity Program For MariTide

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

See All
UsernamePublicRestriction

Register

SC006412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By